array:24 [
  "pii" => "S1578219018301240"
  "issn" => "15782190"
  "doi" => "10.1016/j.adengl.2018.04.006"
  "estado" => "S300"
  "fechaPublicacion" => "2018-06-01"
  "aid" => "1802"
  "copyright" => "Elsevier España, S.L.U. and AEDV"
  "copyrightAnyo" => "2017"
  "documento" => "article"
  "crossmark" => 1
  "subdocumento" => "sco"
  "cita" => "Actas Dermosifiliogr. 2018;109:443-4"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 53
    "formatos" => array:2 [
      "HTML" => 51
      "PDF" => 2
    ]
  ]
  "Traduccion" => array:1 [
    "es" => array:19 [
      "pii" => "S0001731017305161"
      "issn" => "00017310"
      "doi" => "10.1016/j.ad.2017.08.011"
      "estado" => "S300"
      "fechaPublicacion" => "2018-06-01"
      "aid" => "1802"
      "copyright" => "AEDV"
      "documento" => "article"
      "crossmark" => 1
      "subdocumento" => "sco"
      "cita" => "Actas Dermosifiliogr. 2018;109:443-4"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 259
        "formatos" => array:2 [
          "HTML" => 148
          "PDF" => 111
        ]
      ]
      "es" => array:11 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Foro de Residentes</span>"
        "titulo" => "FR-Despu&#233;s de d&#233;cadas sin novedades&#44; nuevos f&#225;rmacos prometen revolucionar el tratamiento de la dermatitis at&#243;pica"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "443"
            "paginaFinal" => "444"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "After Decades Without any Developments&#44; New Drugs May Revolutionize the Treatment of Atopic Dermatitis"
          ]
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:7 [
            "identificador" => "fig0005"
            "etiqueta" => "Figura 1"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "gr1.jpeg"
                "Alto" => 1636
                "Ancho" => 1250
                "Tamanyo" => 283394
              ]
            ]
            "descripcion" => array:1 [
              "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Dermatitis at&#243;pica grave&#46; Se observan m&#250;ltiples erosiones&#44; p&#225;pulas excoriadas y marcada xerosis cut&#225;nea en la espalda&#46;</p>"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "D&#46; Morgado-Carrasco, X&#46; Fust&#224;-Novell, J&#46; Riera-Monroig, P&#46; Iranzo"
            "autores" => array:4 [
              0 => array:2 [
                "nombre" => "D&#46;"
                "apellidos" => "Morgado-Carrasco"
              ]
              1 => array:2 [
                "nombre" => "X&#46;"
                "apellidos" => "Fust&#224;-Novell"
              ]
              2 => array:2 [
                "nombre" => "J&#46;"
                "apellidos" => "Riera-Monroig"
              ]
              3 => array:2 [
                "nombre" => "P&#46;"
                "apellidos" => "Iranzo"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S1578219018301240"
          "doi" => "10.1016/j.adengl.2018.04.006"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018301240?idApp=UINPBA000044"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731017305161?idApp=UINPBA000044"
      "url" => "/00017310/0000010900000005/v2_201806270447/S0001731017305161/v2_201806270447/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S1578219018301276"
    "issn" => "15782190"
    "doi" => "10.1016/j.adengl.2018.04.009"
    "estado" => "S300"
    "fechaPublicacion" => "2018-06-01"
    "aid" => "1830"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and AEDV"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "sco"
    "cita" => "Actas Dermosifiliogr. 2018;109:445"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 54
      "formatos" => array:3 [
        "EPUB" => 1
        "HTML" => 52
        "PDF" => 1
      ]
    ]
    "en" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Images in Dermatology</span>"
      "titulo" => "Indurated Nodule on the Upper Lip"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:1 [
          "paginaInicial" => "445"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "N&#243;dulo indurado en labio superior"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:6 [
          "identificador" => "fig0005"
          "etiqueta" => "Figure 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 994
              "Ancho" => 958
              "Tamanyo" => 194082
            ]
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "A&#46; Imbern&#243;n-Moya, E&#46; Fern&#225;ndez-Cogolludo, M&#46;&#193;&#46; Gallego-Vald&#233;s"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Imbern&#243;n-Moya"
            ]
            1 => array:2 [
              "nombre" => "E&#46;"
              "apellidos" => "Fern&#225;ndez-Cogolludo"
            ]
            2 => array:2 [
              "nombre" => "M&#46;&#193;&#46;"
              "apellidos" => "Gallego-Vald&#233;s"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0001731017305860"
        "doi" => "10.1016/j.ad.2017.03.022"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731017305860?idApp=UINPBA000044"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018301276?idApp=UINPBA000044"
    "url" => "/15782190/0000010900000005/v1_201806040407/S1578219018301276/v1_201806040407/en/main.assets"
  ]
  "itemAnterior" => array:19 [
    "pii" => "S1578219018301203"
    "issn" => "15782190"
    "doi" => "10.1016/j.adengl.2018.04.003"
    "estado" => "S300"
    "fechaPublicacion" => "2018-06-01"
    "aid" => "1761"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and AEDV"
    "documento" => "simple-article"
    "crossmark" => 1
    "subdocumento" => "crp"
    "cita" => "Actas Dermosifiliogr. 2018;109:441-2"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 53
      "HTML" => 53
    ]
    "en" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Case for Diagnosis</span>"
      "titulo" => "A Facial Plaque and Nodules on the Scalp"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "441"
          "paginaFinal" => "442"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Placa facial y n&#243;dulos en cuero cabelludo"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0010"
          "etiqueta" => "Figure 2"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr2.jpeg"
              "Alto" => 697
              "Ancho" => 2333
              "Tamanyo" => 416139
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">A&#44; hematoxylin&#8211;eosin&#44; original magnification &#215;10&#46; B&#44; hematoxylin-eosin&#44; original magnification &#215;40&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "M&#46;&#193;&#46; Flores-Terry, M&#46;P&#46; Cortina de la Calle, C&#46; Ramos-Rodr&#237;guez, F&#46; Mart&#237;n-D&#225;vila"
          "autores" => array:4 [
            0 => array:2 [
              "nombre" => "M&#46;&#193;&#46;"
              "apellidos" => "Flores-Terry"
            ]
            1 => array:2 [
              "nombre" => "M&#46;P&#46; Cortina de la"
              "apellidos" => "Calle"
            ]
            2 => array:2 [
              "nombre" => "C&#46;"
              "apellidos" => "Ramos-Rodr&#237;guez"
            ]
            3 => array:2 [
              "nombre" => "F&#46;"
              "apellidos" => "Mart&#237;n-D&#225;vila"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0001731017303897"
        "doi" => "10.1016/j.ad.2016.12.026"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731017303897?idApp=UINPBA000044"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018301203?idApp=UINPBA000044"
    "url" => "/15782190/0000010900000005/v1_201806040407/S1578219018301203/v1_201806040407/en/main.assets"
  ]
  "en" => array:15 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Resident&#39;s Forum</span>"
    "titulo" => "After Decades Without any Developments&#44; New Drugs May Revolutionize the Treatment of Atopic Dermatitis"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "443"
        "paginaFinal" => "444"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "D&#46; Morgado-Carrasco, X&#46; Fust&#224;-Novell, J&#46; Riera-Monroig, P&#46; Iranzo"
        "autores" => array:4 [
          0 => array:2 [
            "nombre" => "D&#46;"
            "apellidos" => "Morgado-Carrasco"
          ]
          1 => array:2 [
            "nombre" => "X&#46;"
            "apellidos" => "Fust&#224;-Novell"
          ]
          2 => array:2 [
            "nombre" => "J&#46;"
            "apellidos" => "Riera-Monroig"
          ]
          3 => array:4 [
            "nombre" => "P&#46;"
            "apellidos" => "Iranzo"
            "email" => array:1 [
              0 => "piranzo&#64;clinic&#46;cat"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:2 [
            "entidad" => "Dermatology Department&#44; Hospital Cl&#237;nic de Barcelona&#44; Universitat de Barcelona&#44; Barcelona&#44; Spain"
            "identificador" => "aff0005"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "FR-Despu&#233;s de d&#233;cadas sin novedades&#44; nuevos f&#225;rmacos prometen revolucionar el tratamiento de la dermatitis at&#243;pica"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 1636
            "Ancho" => 1250
            "Tamanyo" => 284264
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Severe atopic dermatitis&#46; Note the multiple erosions&#44; excoriated papules&#44; and marked xerosis on the back&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Atopic dermatitis &#40;AD&#41; is an inflammatory skin disease characterized by pruritic eczematous lesions that can affect large surface areas of the body &#40;<a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a>&#41;&#46; Etiologic and pathogenic mechanisms include epithelial dysfunction&#44; alterations to gut microbiota&#44; and inadequate immune activation with overexpression of interleukin 4 &#40;IL-4&#41;&#44; IL-13&#44; and IL-31&#46;<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">1</span></a> Severe AD requires systemic treatment with oral corticosteroids and immunosuppressive agents&#44; but the long-term use of these drugs can cause considerable adverse effects&#46; Despite the prevalence of AD&#44; no new drugs have been developed in recent decades&#46; The US Food and Drug Administration&#44; however&#44; recently approved 2 novel drugs&#44; dupilumab and crisaborole&#44; for use in AD&#44; and other drugs have shown promising results in preliminary studies&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0010" class="elsevierStylePara elsevierViewall">Dupilumab blocks the IL-4 receptor &#945; subunit&#44; thereby inhibiting IL-4 and IL-13 signaling and reducing not only the production of immunoglobulin E but also inflammatory responses mediated by type 2 helper T cells&#46; Two randomized placebo-controlled clinical trials of dupilumab in patients with moderate to severe AD&#44; SOLO-1 &#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>671&#41; and SOLO-2 &#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>708&#41;&#44; found that dupilumab 300<span class="elsevierStyleHsp" style=""></span>mg administered subcutaneously every week or every 2 weeks resulted in an investigator&#39;s global assessment &#40;IGA&#41; score of 0 or 1 &#40;clear or almost clear&#41; at 16 weeks in 38&#37; of patients &#40;vs&#46; 10&#37; for placebo&#41; in SOLO-1 and 36&#37; &#40;vs&#46; 8&#37; for placebo&#41; in SOLO-2 &#40;<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>&#46;001&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">2</span></a> It was also associated with a greater percent reduction in the Eczema Area and Severity Index &#40;EASI&#41; score &#40;67&#37; to 72&#37; vs&#46; 30&#37; to 37&#37; for placebo&#44; <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>&#46;001&#41; and better results on all the clinical evaluation&#44; quality of life&#44; and pruritus scales&#46; Adverse effects were similar in both groups&#44; although dupilumab was inexplicably associated with a higher incidence of conjunctivitis&#46;</p><p id="par0015" class="elsevierStylePara elsevierViewall">Topical crisaborole 2&#37; is a nonsteroidal anti-inflammatory drug that inhibits phosphodiesterase &#40;PDE&#41; 4 &#40;mainly PDE4B&#41;&#44; reducing the release of proinflammatory cytokines&#44; such as tumor necrosis factor&#44; IL-12&#44; and IL-23&#46; Two clinical trials in patients older than 2 years with mild to moderate AD&#44; AD&#58;301 &#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>763&#41; and AD&#58;302 &#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>764&#41;&#44; found crisaborole to be superior to placebo in terms of reducing IgA after 28 days &#40;AD&#58;301&#58; 32&#46;8&#37; vs&#46; 25&#46;4&#37;&#44; <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>&#46;038&#59; AD&#58;302&#58; 31&#46;4&#37; vs&#46; 18&#46;0&#37;&#44; <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>&#46;001&#41; and improving pruritus&#46;<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">3</span></a> In addition&#44; adverse effects were minimal&#46;</p><p id="par0020" class="elsevierStylePara elsevierViewall">One interesting drug currently being investigated in clinical trials is nemolizumab&#46; Nemolizumab is a monoclonal anti-IL-31 receptor antibody that has been shown to be superior to placebo in a phase II trial of 264 patients with moderate to severe AD&#46; It was more effective in improving pruritus &#40;percentage improvement from baseline of 63&#37; in the high-dose group vs&#46; 21&#37; for placebo&#41;&#44; although it did not reduce the body surface area affected&#46;<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">4</span></a> Another promising drug is topical tofacitinib 2&#37;&#44; which inhibits janus kinases 1 and 3 and the activity of IL-2&#44; IL-4&#44; and other proinflammatory cytokines&#46; The results of a phase IIa trial of 69 adults with mild to moderate AD showed that topical tofacitinib 2&#37; was significantly superior to placebo in terms of improving EASI score &#40;&#8722;81&#46;7&#37; vs&#46; &#8722;29&#46;9&#37;&#41; and pruritus&#46; There were also few treatment-related effects&#46;<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">5</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">Dupilumab and crisaborole have emerged as novel dermatological treatments&#44; and dupilumab in particular seems poised to revolutionize the treatment of moderate to severe AD&#46; Further studies of IL-31&#44; IL-13&#44; and JAK inhibitors will determine their efficacy and safety&#46; Patients will benefit from safe&#44; effective drugs that are better tolerated than corticosteroids and other immunosuppressive agents&#46;</p></span>"
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:1 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec990664"
          "palabras" => array:6 [
            0 => "Atopic dermatitis"
            1 => "Pruritus"
            2 => "Dupilumab"
            3 => "Crisaborole"
            4 => "Nemolizumab"
            5 => "Tofacitinib"
          ]
        ]
      ]
    ]
    "NotaPie" => array:1 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as&#58; Morgado-Carrasco D&#44; Fust&#224;-Novell X&#44; Riera-Monroig J&#44; Iranzo P&#46; FR-Despu&#233;s de d&#233;cadas sin novedades&#44; nuevos f&#225;rmacos prometen revolucionar el tratamiento de la dermatitis at&#243;pica&#46; Actas Dermosifiliogr&#46; 2018&#59;109&#58;443&#8211;444&#46;</p>"
      ]
    ]
    "multimedia" => array:1 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 1636
            "Ancho" => 1250
            "Tamanyo" => 284264
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Severe atopic dermatitis&#46; Note the multiple erosions&#44; excoriated papules&#44; and marked xerosis on the back&#46;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:5 [
            0 => array:3 [
              "identificador" => "bib0030"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Dupilumab in the treatment of moderate-to-severe atopic dermatitis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "M&#46; Kraft"
                            1 => "M&#46; Worm"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1080/1744666X.2017.1292134"
                      "Revista" => array:6 [
                        "tituloSerie" => "Expert Rev Clin Immunol"
                        "fecha" => "2017"
                        "volumen" => "13"
                        "paginaInicial" => "301"
                        "paginaFinal" => "310"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28165826"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0035"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "E&#46;L&#46; Simpson"
                            1 => "B&#46; Akinlade"
                            2 => "M&#46; Ardeleanu"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMc1700366"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2017"
                        "volumen" => "376"
                        "paginaInicial" => "1090"
                        "paginaFinal" => "1091"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28301105"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0040"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:3 [
                  "comentario" => "e4"
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and safety of crisaborole ointment&#44; a novel&#44; nonsteroidal phosphodiesterase 4 &#40;PDE4&#41; inhibitor for the topical treatment of atopic dermatitis &#40;AD&#41; in children and adults"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46;S&#46; Paller"
                            1 => "W&#46;L&#46; Tom"
                            2 => "M&#46;G&#46; Lebwohl"
                            3 => "R&#46;L&#46; Blumenthal"
                            4 => "M&#46; Boguniewicz"
                            5 => "R&#46;S&#46; Call"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2016.05.046"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol"
                        "fecha" => "2016"
                        "volumen" => "75"
                        "paginaInicial" => "494"
                        "paginaFinal" => "503"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27417017"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0045"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "T&#46; Ruzicka"
                            1 => "J&#46;M&#46; Hanifin"
                            2 => "M&#46; Furue"
                            3 => "G&#46; Pulka"
                            4 => "I&#46; Mlynarczyk"
                            5 => "A&#46; Wollenberg"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1606490"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2017"
                        "volumen" => "376"
                        "paginaInicial" => "826"
                        "paginaFinal" => "835"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28249150"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0050"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Topical tofacitinib for atopic dermatitis&#58; A phase IIa randomized trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "R&#46; Bissonnette"
                            1 => "K&#46;A&#46; Papp"
                            2 => "Y&#46; Poulin"
                            3 => "M&#46; Gooderham"
                            4 => "M&#46; Raman"
                            5 => "L&#46; Mallbris"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/bjd.14871"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol"
                        "fecha" => "2016"
                        "volumen" => "175"
                        "paginaInicial" => "902"
                        "paginaFinal" => "911"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27423107"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/15782190/0000010900000005/v1_201806040407/S1578219018301240/v1_201806040407/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "34945"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Resident&#39;s Forum"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/15782190/0000010900000005/v1_201806040407/S1578219018301240/v1_201806040407/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018301240?idApp=UINPBA000044"
]
Compartir
Información de la revista
Vol. 109. Núm. 5.
Páginas 443-444 (junio 2018)
Vol. 109. Núm. 5.
Páginas 443-444 (junio 2018)
Resident's Forum
Acceso a texto completo
After Decades Without any Developments, New Drugs May Revolutionize the Treatment of Atopic Dermatitis
FR-Después de décadas sin novedades, nuevos fármacos prometen revolucionar el tratamiento de la dermatitis atópica
Visitas
6106
D. Morgado-Carrasco, X. Fustà-Novell, J. Riera-Monroig, P. Iranzo
Autor para correspondencia
piranzo@clinic.cat

Corresponding author.
Dermatology Department, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain
Este artículo ha recibido
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Figuras (1)
Texto completo

Atopic dermatitis (AD) is an inflammatory skin disease characterized by pruritic eczematous lesions that can affect large surface areas of the body (Fig. 1). Etiologic and pathogenic mechanisms include epithelial dysfunction, alterations to gut microbiota, and inadequate immune activation with overexpression of interleukin 4 (IL-4), IL-13, and IL-31.1 Severe AD requires systemic treatment with oral corticosteroids and immunosuppressive agents, but the long-term use of these drugs can cause considerable adverse effects. Despite the prevalence of AD, no new drugs have been developed in recent decades. The US Food and Drug Administration, however, recently approved 2 novel drugs, dupilumab and crisaborole, for use in AD, and other drugs have shown promising results in preliminary studies.

Figure 1.

Severe atopic dermatitis. Note the multiple erosions, excoriated papules, and marked xerosis on the back.

(0.27MB).

Dupilumab blocks the IL-4 receptor α subunit, thereby inhibiting IL-4 and IL-13 signaling and reducing not only the production of immunoglobulin E but also inflammatory responses mediated by type 2 helper T cells. Two randomized placebo-controlled clinical trials of dupilumab in patients with moderate to severe AD, SOLO-1 (n=671) and SOLO-2 (n=708), found that dupilumab 300mg administered subcutaneously every week or every 2 weeks resulted in an investigator's global assessment (IGA) score of 0 or 1 (clear or almost clear) at 16 weeks in 38% of patients (vs. 10% for placebo) in SOLO-1 and 36% (vs. 8% for placebo) in SOLO-2 (P<.001).2 It was also associated with a greater percent reduction in the Eczema Area and Severity Index (EASI) score (67% to 72% vs. 30% to 37% for placebo, P<.001) and better results on all the clinical evaluation, quality of life, and pruritus scales. Adverse effects were similar in both groups, although dupilumab was inexplicably associated with a higher incidence of conjunctivitis.

Topical crisaborole 2% is a nonsteroidal anti-inflammatory drug that inhibits phosphodiesterase (PDE) 4 (mainly PDE4B), reducing the release of proinflammatory cytokines, such as tumor necrosis factor, IL-12, and IL-23. Two clinical trials in patients older than 2 years with mild to moderate AD, AD:301 (n=763) and AD:302 (n=764), found crisaborole to be superior to placebo in terms of reducing IgA after 28 days (AD:301: 32.8% vs. 25.4%, P=.038; AD:302: 31.4% vs. 18.0%, P<.001) and improving pruritus.3 In addition, adverse effects were minimal.

One interesting drug currently being investigated in clinical trials is nemolizumab. Nemolizumab is a monoclonal anti-IL-31 receptor antibody that has been shown to be superior to placebo in a phase II trial of 264 patients with moderate to severe AD. It was more effective in improving pruritus (percentage improvement from baseline of 63% in the high-dose group vs. 21% for placebo), although it did not reduce the body surface area affected.4 Another promising drug is topical tofacitinib 2%, which inhibits janus kinases 1 and 3 and the activity of IL-2, IL-4, and other proinflammatory cytokines. The results of a phase IIa trial of 69 adults with mild to moderate AD showed that topical tofacitinib 2% was significantly superior to placebo in terms of improving EASI score (−81.7% vs. −29.9%) and pruritus. There were also few treatment-related effects.5

Dupilumab and crisaborole have emerged as novel dermatological treatments, and dupilumab in particular seems poised to revolutionize the treatment of moderate to severe AD. Further studies of IL-31, IL-13, and JAK inhibitors will determine their efficacy and safety. Patients will benefit from safe, effective drugs that are better tolerated than corticosteroids and other immunosuppressive agents.

References
[1]
M. Kraft, M. Worm.
Dupilumab in the treatment of moderate-to-severe atopic dermatitis.
Expert Rev Clin Immunol, 13 (2017), pp. 301-310
[2]
E.L. Simpson, B. Akinlade, M. Ardeleanu.
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
N Engl J Med, 376 (2017), pp. 1090-1091
[3]
A.S. Paller, W.L. Tom, M.G. Lebwohl, R.L. Blumenthal, M. Boguniewicz, R.S. Call, et al.
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
J Am Acad Dermatol, 75 (2016), pp. 494-503
e4
[4]
T. Ruzicka, J.M. Hanifin, M. Furue, G. Pulka, I. Mlynarczyk, A. Wollenberg, et al.
Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis.
N Engl J Med, 376 (2017), pp. 826-835
[5]
R. Bissonnette, K.A. Papp, Y. Poulin, M. Gooderham, M. Raman, L. Mallbris, et al.
Topical tofacitinib for atopic dermatitis: A phase IIa randomized trial.
Br J Dermatol, 175 (2016), pp. 902-911

Please cite this article as: Morgado-Carrasco D, Fustà-Novell X, Riera-Monroig J, Iranzo P. FR-Después de décadas sin novedades, nuevos fármacos prometen revolucionar el tratamiento de la dermatitis atópica. Actas Dermosifiliogr. 2018;109:443–444.

Copyright © 2017. Elsevier España, S.L.U. and AEDV
Descargar PDF
Idiomas
Actas Dermo-Sifiliográficas
Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?